Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Payables (2020 - 2025)

Apellis Pharmaceuticals has reported Payables over the past 6 years, most recently at $56.8 million for Q4 2025.

  • Quarterly results put Payables at $56.8 million for Q4 2025, up 47.25% from a year ago — trailing twelve months through Dec 2025 was $56.8 million (up 47.25% YoY), and the annual figure for FY2025 was $56.8 million, up 47.25%.
  • Payables for Q4 2025 was $56.8 million at Apellis Pharmaceuticals, up from $38.6 million in the prior quarter.
  • Over the last five years, Payables for APLS hit a ceiling of $56.8 million in Q4 2025 and a floor of $4.2 million in Q1 2021.
  • Median Payables over the past 5 years was $29.5 million (2023), compared with a mean of $28.9 million.
  • Biggest five-year swings in Payables: crashed 54.97% in 2021 and later surged 203.8% in 2022.
  • Apellis Pharmaceuticals' Payables stood at $16.9 million in 2021, then surged by 120.84% to $37.3 million in 2022, then grew by 0.47% to $37.5 million in 2023, then rose by 2.81% to $38.6 million in 2024, then surged by 47.25% to $56.8 million in 2025.
  • The last three reported values for Payables were $56.8 million (Q4 2025), $38.6 million (Q3 2025), and $54.2 million (Q2 2025) per Business Quant data.